| Study | Pathogen | Total £ S1 | Total £ S2 | Total QALYs S1 | Total QALYs S2 | Inc. costs | Inc. QALYs | ICER |
|---|---|---|---|---|---|---|---|---|
| France 2008 | Intermittent BCC | £1,357,488 | £895,680 | 210.69 | 212.05 | £461,808 | −1.37 | Dominated |
| Whitford 1995 | Intermittent BCC | £914,521 | £1,050,954 | 212.26 | 211.50 | −£136,433 | 0.76 | Dominant |
| Federiksen 1999 | Intermittent PA | £1,116,939 | £827,033 | 210.00 | 208.79 | £289,906 | 1.20 | £241,185 |
| Lee 2004 (prevalence) | Intermittent PA | £1,137,291 | £814,992 | 208.66 | 209.58 | £322,299 | −0.92 | Dominated |
| Lee 2004 (incidence 1990 versus 2000) | Intermittent PA | £1,19,659 | £818,045 | 209.16 | 209.38 | £311,615 | −0.22 | Dominated |
| Lee 2004 (incidence 1990 versus average 1991–2000) | Intermittent PA | £1,144,923 | £818,045 | 208.16 | 209.38 | £326,879 | −1.22 | Dominated |
| Federiksen 1999 | Chronic PA | £1,639,441 | £1,870,334 | 207.60 | 202.84 | −£230,893 | 4.76 | Dominant |
| Hoiby 1989 | Chronic PA | £4,136,118 | £5,922,151 | 185.77 | 167.23 | −£1,786,033 | 18.54 | Dominant |
| Lee 2004 (prevalence) | Chronic PA | £2,079,079 | £2,117,784 | 203.75 | 200.66 | −£38,705 | 3.09 | Dominant |
BCC, B cepacia complex; ICER, idomncremental cost-effectiveness ratio; PA, P aeruginosa; QALYs, quality-adjusted life years; S1, new strategy; S2, old strategy
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.